Substance / Medication

Niraparib

Overview

Active Ingredient
niraparib
RxNorm CUI
1918231

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

18 trials linked to this intervention

18
Total Trials
16
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Safety of niraparib-based regimens in patients with ovarian cancer: A systematic review and meta-analysis.
Tayyab Muhammad, Butt Zuhair Ahmed, Kamala Kondraju Preethi et al. · Eur J Obstet Gynecol Reprod Biol · 2025
PMID: 39908743Meta-Analysis
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Pagkali Antonia, Mamais Ioannis, Michalinos Adamantios et al. · Curr Oncol · 2022
PMID: 35049703Meta-AnalysisFull text (PMC)
Dostarlimab and niraparib in primary advanced ovarian cancer.
Hardy-Bessard A-C, Pujade-Lauraine E, Moore R G et al. · Ann Oncol · 2025
PMID: 40461381RCT
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Matulonis Ursula A, Herrstedt Jørn, Oza Amit et al. · Gynecol Oncol · 2025
PMID: 40139026RCT
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Falchook Gerald, Patnaik Amita, Richardson Debra L et al. · Clin Ther · 2024
PMID: 38423866RCT
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Vulsteke Christof, Chambers Setsuko K, Pérez Maria Jesús Rubio et al. · Eur J Cancer · 2024
PMID: 39013265RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Niraparib (substance)
SNOMED CT
733733005
UMLS CUI
C2744440
RxNorm CUI
1918231

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
18
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.